Governmental initiative on the evaluation of commercial COVID-19 tests in England

11

Dec 2020

The Department of Health and Social Care announced its new national testing strategy, which aimed to scale up testing programs for COVID-19. To reach the aim, the evaluation process of virus detection and antibody detection tests to place the test kit on the market in the UK was initiated. The call for proposals to supply antibody detection tests has been closed, but proposals for virus detection tests are still ongoing.

To be evaluated, the test should meet the Targets Product Profile (TPP) criteria that have been developed to help manufacturers design and deliver tests. If the test meets the TPP,  or if the test does not match the specifications of the TPP but looks promising, the proposal should be submitted via the DHSC portal. The DHSC has a set process for the evaluation of diagnostic tests for COVID-19, as well as for multiplex respiratory virus tests. The process of evaluation is possible for CE marked and non-CE-marked tests (with the additional step of applying for a derogation).

Test kit manufacturers are required to make claims about the expected performance of their test kit before they can place the test kit on the market in the UK. The claims include analytical sensitivity, diagnostic sensitivity, analytical specificity, diagnostic specificity, accuracy, repeatability, reproducibility, including control of known relevant interference, limits of detection.

The full details in English can be found here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).

The latest related news

18

Mar 2022

On February 22, 2022, a repository of innovative acts outside the nomenclature of biology and anatomopathology (RIHN) and a Supplementary list of IVD tests were published. Minor changes were introduced in the 2022 RIHN list.

Read more

25

Feb 2022

The Council for Choices in Health Care in Finland (PALKO) has discontinued the development of recommendations concerning companion diagnostic tests. The respective preparations were completed in November 2021.

Read more

23

Feb 2022

On January 24, 2022, the Norwegian Directorate of e-Health released an updated version of the National Laboratory code (NLK) system and associated tariffs for state and private laboratories to be implemented no later than March 01, 2022. NLK system has been used for activity-based reimbursement by the Norwegian Health Economics Administration (Helfo) in outpatient settings since 2018. Thirty new codes were added medical biochemistry, medical microbiology, immunology and transfusiology, and clinical pharmacology areas.

Read more

07

Jan 2022

In late December 2021, five new in-vitro diagnostics tests, including one test for COVID-19 spike protein antibodies determination, were added to the Laboratory Test Nomenclature (Laboratoriotutkimusnimikkeistö) in Finland.

Read more

30

Dec 2021

The Council for Choices in Health Care in Finland (PALKO) has initiated the development of recommendations concerning companion diagnostic tests. The respective preparations were completed in November 2021.

Read more